Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other financing activities: 2011-2025

Historic Other financing activities for Lineage Cell Therapeutics (LCTX) over the last 8 years, with Mar 2025 value amounting to $15,000.

  • Lineage Cell Therapeutics' Other financing activities fell 34.78% to $15,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $1.1 million, marking a year-over-year decrease of 52.49%. This contributed to the annual value of $23,000 for FY2024, which is 37.84% down from last year.
  • According to the latest figures from Q1 2025, Lineage Cell Therapeutics' Other financing activities is $15,000, which was down 34.78% from $23,000 recorded in Q1 2024.
  • In the past 5 years, Lineage Cell Therapeutics' Other financing activities ranged from a high of $1.3 million in Q2 2023 and a low of -$162,000 during Q4 2023.
  • For the 3-year period, Lineage Cell Therapeutics' Other financing activities averaged around $410,333, with its median value being $30,000 (2023).
  • In the last 5 years, Lineage Cell Therapeutics' Other financing activities soared by 128.34% in 2021 and then plummeted by 1,572.73% in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Other financing activities (Quarterly) stood at $917,000 in 2021, then crashed by 98.80% to $11,000 in 2022, then crashed by 1,572.73% to -$162,000 in 2023, then crashed by 37.84% to $23,000 in 2024, then crashed by 34.78% to $15,000 in 2025.
  • Its Other financing activities was $15,000 in Q1 2025, compared to $23,000 in Q1 2024 and -$162,000 in Q4 2023.